Company Overview of INO Therapeutics LLC
INO Therapeutics LLC provides inhaled nitric oxide, an inhaled drug for treating hypoxic respiratory failure in newborns greater than 34 weeks gestational age. The company also offers INOmax DSIR line of delivery systems. It improves oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. INO Therapeutics LLC was formerly known as INOCO, Inc. and changed its name to INO Therapeutics LLC in November 2003. The company was founded in 1998 and is ...
53 Frontage Road
Perryville III Corporate Park
P.O. Box 9001
Hampton, NJ 08827-9001
Founded in 1998
Key Executives for INO Therapeutics LLC
INO Therapeutics LLC does not have any Key Executives recorded.
INO Therapeutics LLC Key Developments
Therapeutics, Inc. Enters into Second Amendment to the Exclusive Cross-License, Technology Transfer, and Regulatory Matters Agreement with INO Therapeutics LLC
Jul 31 15
On July 27, 2015, Bellerophon Pulse Technologies LLC entered into a second amendment to the Exclusive Cross-License, Technology Transfer, and Regulatory Matters Agreement, dated as of February 9, 2014, between Pulse Technologies and INO Therapeutics LLC. The parties entered into the Cross-License in connection with the Company’s spin-out from Ikaria. The Amendment expands the scope of the Company’s license from INO Therapeutics under the Cross-License to allow the Company to develop its INOpulse program for the treatment of three additional cardiopulmonary diseases: chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary hypertension associated with sarcoidosis and pulmonary hypertension associated with pulmonary edema from high altitude sickness. Subject to the terms set therein, the Amendment also provides that the Company will pay INO Therapeutics a royalty equal to 5% of Net Sales (as defined in the Amendment) of any commercialized products for the three additional indications.
INO Therapeutics and Lee's Pharmaceutical (HK) Limited Sign Strategic Partnership for the Registration and Commercialization of Ikaria's INOMAX(R) Total Care Package Throughout the People's Republic of China
Nov 19 14
Ikaria Inc. through its INO Therapeutics subsidiary and Lee's Pharmaceutical (HK) Limited announced the signing of a strategic partnership for the registration and commercialization of Ikaria's INOMAX(R) Total Care package throughout the People's Republic of China, Hong Kong, Macau and Taiwan. Financial terms of the partnership were not disclosed. INOMAX(R) (inhaled nitric oxide) is the only therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypoxic respiratory failure (HRF) associated with pulmonary hypertension in term and near-term infants greater than 34 weeks gestational age. HRF is a serious condition in which blood vessels in the lungs constrict, making it difficult to oxygenate blood. INOMAX(R) is a vasodilator which selectively relaxes pulmonary blood vessels and, in conjunction with ventilatory support and other appropriate agents, improves oxygenation in this fragile newborn population. INOMAX(R) Total Care is Ikaria's all inclusive offering of the INOMAX(R) drug, along with a drug-delivery system, training, and 24/7 technical assistance and support. In addition to the United States, INOMAX(R) has been approved and is currently commercialized by Ikaria and its partners in Australia, Canada, Europe, Japan, South Korea and select countries in South America.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries